Corium International,Inc. (NASDAQ:CORI) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

Corium International,Inc. (NASDAQ:CORI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.      Entry into a Material Definitive Agreement.

On April 25, 2017,  Corium International, Inc. (the “Company”) and The Procter & Gamble Manufacturing Company (“P&G”) entered into a commercial supply agreement (the “Supply Agreement”), effective May 1, 2017.   to the Supply Agreement, the Company will continue to produce and supply to P&G oral care products that are sold under the brand name Crest Whitestrips, at specified pricing levels. The Supply Agreement will remain in effect until March 31, 2022,  absent early termination for material uncured breach.  

The foregoing summary of the Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the Supply Agreement, which will be filed with the U.S. Securities and Exchange Commission (the “SEC”) as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended April 30, 2017. The Company intends to seek confidential treatment for certain portions of the Supply Agreement to a Confidential Treatment Request to be submitted to the SEC to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

The Supply Agreement is part of a multi-faceted strategic arrangement between the Company and P&G as described in further detail in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016 that was filed with the SEC on December 20, 2016.

2


About Corium International, Inc. (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Corium International, Inc. (NASDAQ:CORI) Recent Trading Information

Corium International, Inc. (NASDAQ:CORI) closed its last trading session down -0.01 at 4.51 with 5,809 shares trading hands.